Restatement of Previously Reported Unaudited Interim Consolidated Financial Statements (Unaudited) - Consolidated Statements of Income (Loss) (Details) - USD ($)		3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Nov. 16, 2020	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Costs and Expenses:
General and administrative		$ 2,416,000	$ 1,541,000		$ 3,196,000	$ 5,612,000	$ 9,858,000	$ 6,474,000
Research and development expense		2,570,000	3,485,000		6,082,000	8,652,000	11,723,000	7,800,000
Total Operating Costs and Expenses		4,986,000	5,026,000		9,278,000	14,264,000	21,581,000	14,274,000
Loss from Operations		(4,986,000)	(5,026,000)		(9,278,000)	(14,264,000)	(21,581,000)	(14,274,000)
Other Income:
Exchange loss		(9,000)	(9,000)		(31,000)	(40,000)	(41,000)	0
Interest income		170,000	26,000		27,000	197,000	512,000	6,000
Total Other Income(Expense)		161,000	17,000		(4,000)	157,000	471,000	6,000
Net Loss before income taxes		(4,825,000)	(5,009,000)		(9,282,000)	(14,107,000)	(21,110,000)	(14,268,000)
Income tax benefit		335,000	532,000		532,000	867,000	1,425,000	0
Net loss		(4,490,000)	(4,477,000)		(8,750,000)	(13,240,000)	(19,685,000)	(14,268,000)
Net loss attributable to non-controlling interest							0	(1,000)
Net loss		(4,490,000)	(4,477,000)	$ (4,273,000)	(8,750,000)	(13,240,000)	(19,685,000)	(14,267,000)
Effect of Warrant exercise price adjustment		(340,000)				(340,000)	(340,000)	0
Effect of Series A Preferred Stock price adjustment							0	(7,402,000)
Net loss attributable to common stockholders			$ (4,477,000)		$ (8,750,000)	$ (13,580,000)	$ (20,025,000)	$ (23,189,000)
Net Loss Attributable to Common Stockholders		$ (4,830,000)
Net Loss Per Share - Basic		$ (0.30)	$ (0.28)		$ (0.59)	$ (0.87)	$ (1.31)	$ (1.90)
Net Loss Per Share - Dilutive			$ (0.28)		$ (0.59)	$ (0.87)	$ (1.31)	$ (1.90)
Weighted average number of shares outstanding during the period - Basic		15,844,061	15,844,061		14,837,832	15,176,927	15,327,328	12,187,504
Weighted average number of shares outstanding during the period - Dilutive		15,844,061	15,844,061		14,837,832	15,176,927	15,327,328	12,187,504
Loss on foreign currency translation		$ (1,527,000)	$ (1,497,000)		$ (1,317,000)	$ (2,844,000)	$ (679,000)	$ 0
Total comprehensive loss		(6,017,000)	(5,974,000)		(10,067,000)	(16,084,000)	(20,364,000)	(14,268,000)
Comprehensive loss attributable to non-controlling interest							0	(1,000)
Comprehensive loss attributable to Synthetic Biologics, s, , Inc. . and Subsidiaries		(6,017,000)	(5,974,000)		(10,067,000)	(16,084,000)	$ (20,364,000)	(14,267,000)
Series A Preferred Stock
Other Income:
Preferred Stock Dividends								(24,000)	$ (254,000)
Effect of Series A Preferred Stock price adjustment								(7,402,000)
Series B Preferred Stock
Other Income:
Effect of Warrant exercise price adjustment	$ (880,000,000,000)
Preferred Stock Dividends								$ (1,496,000)
As Previously Reported
Operating Costs and Expenses:
General and administrative		2,444,000	1,500,000		3,155,000	5,599,000
Research and development expense		2,570,000	3,485,000		6,082,000	8,652,000
Total Operating Costs and Expenses		5,014,000	4,985,000		9,237,000	14,251,000
Loss from Operations		(5,014,000)	(4,985,000)		(9,237,000)	(14,251,000)
Other Income:
Exchange loss		(9,000)	(9,000)		(31,000)	(40,000)
Interest income		170,000	26,000		27,000	197,000
Total Other Income(Expense)		161,000	17,000		(4,000)	157,000
Net Loss before income taxes		(4,853,000)	(4,968,000)		(9,241,000)	(14,094,000)
Net loss		(4,853,000)	(4,968,000)		(9,241,000)	(14,094,000)
Net loss		(4,853,000)	(4,968,000)	$ (4,273,000)	(9,241,000)	(14,094,000)
Effect of Warrant exercise price adjustment		(340,000)				(340,000)
Net loss attributable to common stockholders			$ (4,968,000)		$ (9,241,000)	$ (14,434,000)
Net Loss Attributable to Common Stockholders		$ (5,193,000)
Net Loss Per Share - Basic		$ (0.33)	$ (0.31)		$ (0.62)	$ (0.95)
Net Loss Per Share - Dilutive		$ (0.33)	$ (0.31)		$ (0.62)	$ (0.95)
Weighted average number of shares outstanding during the period - Basic		15,844,061	15,844,061		14,837,832	15,176,927
Weighted average number of shares outstanding during the period - Dilutive		15,844,061	15,844,061		14,837,832	15,176,927
Loss on foreign currency translation		$ (1,527,000)	$ (1,497,000)		$ (1,317,000)	$ (2,844,000)
Total comprehensive loss		(6,380,000)	(6,465,000)		(10,558,000)	(16,938,000)
Comprehensive loss attributable to Synthetic Biologics, s, , Inc. . and Subsidiaries		(6,380,000)	(6,465,000)		(10,558,000)	(16,938,000)
Restatement Adjustments
Other Income:
Income tax benefit		335,000	532,000		532,000	867,000
Net loss		335,000	532,000		532,000	867,000
Net loss		335,000	532,000		532,000	867,000
Net loss attributable to common stockholders			$ 532,000		$ 532,000	$ 867,000
Net Loss Attributable to Common Stockholders		$ 335,000
Net Loss Per Share - Basic		$ 0.03	$ 0.03		$ 0.03	$ 0.08
Net Loss Per Share - Dilutive			$ 0.03		$ 0.03	$ 0.08
Weighted average number of shares outstanding during the period - Dilutive		0	0		0	0
Total comprehensive loss		$ 335,000	$ 532,000		$ 532,000	$ 867,000
Comprehensive loss attributable to Synthetic Biologics, s, , Inc. . and Subsidiaries		335,000	532,000		532,000	867,000
Other Immaterial Adjustments
Operating Costs and Expenses:
General and administrative		(28,000)	41,000		41,000	13,000
Total Operating Costs and Expenses		(28,000)	41,000		41,000	13,000
Loss from Operations		28,000	(41,000)		(41,000)	(13,000)
Other Income:
Net Loss before income taxes		28,000	(41,000)		(41,000)	(13,000)
Net loss		28,000	(41,000)		(41,000)	(13,000)
Net loss		28,000	(41,000)		(41,000)	(13,000)
Net loss attributable to common stockholders			(41,000)		(41,000)	(13,000)
Net Loss Attributable to Common Stockholders		28,000
Total comprehensive loss		28,000	(41,000)		(41,000)	(13,000)
Comprehensive loss attributable to Synthetic Biologics, s, , Inc. . and Subsidiaries		$ 28,000	$ (41,000)		$ (41,000)	$ (13,000)